An interventional study of Early time-restricted eating (eTRE) and Late time-restricted eating (lTRE) in Metabolic Syndrome, Overweight and Obesity and Time Restricted Eating, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment
Investigators aim to compare the effects of early and late time-restricted feeding on overweight adults with metabolic syndrome
1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.
This study's enrollment of 103 is above the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 306 studies on the registry; 86 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
Exclusion Criteria:
The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM
Behavioral: Early time-restricted eating (eTRE)
The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM
Behavioral: Late time-restricted eating (lTRE)
The eTRE group is instructed to consume all calories in early 8h eating window,
The lTRE group is instructed to consume all calories in late 8h eating window.
Changes in body weight
Body weight is assessed at the research center with the participants without shoes and in light clothing using a digital scale (OMRON MEDICAL Beijing Co., Ltd. HNH-318) to the nearest 0.1 kg.
Time frame: 0-week; 6-week and 12-week
Changes in abdominal fat area
Abdominal fat area is measured using bioelectrical impedance analysis (OMRON MEDICAL Beijing Co., Ltd. DUALSCAN, HDS-2000) to the nearest 1 cm2.
Time frame: 0-week; 6-week and 12-week
Changes in body composition ( body fat mass)
Body composition (body fat mass ) is measured using the dual-energy X-ray absorptiometry (DXA, Hologic Serie horzion-wi QDR., Bedford, MA, USA)
Time frame: 0-week and 12-week
Changes in body composition (body muscle mass)
Body composition ( body muscle mass) is measured using the dual-energy X-ray absorptiometry (DXA, Hologic Serie horzion-wi QDR., Bedford, MA, USA)
Time frame: 0-week and 12-week
Changes in glycemic control
Plasma glucose is measured on an automatic biochemistry analyzer (HITACHI, Inc.; LAbOSPECT, 008AS) using standard reagents to the nearest 0.01 mmol/L; Serum insulin is measured by a magnetic particle chemiluminescence immunoassay (Kaeser 6600, Guangzhou Kangrun Co., Ltd., China) to the nearest 0.01 μIU/mL;
Time frame: 0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c)
Changes in hemoglobin A1c (HbA1c)
HbA1c is measured on an automatic HbA1c analyzer (TOSOH BIOSCIENCE, Inc.; HLC-723G8) to the nearest 0.1%.
Time frame: 0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c)
Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)
Plasma lipids of total cholesterol, TG, HDL-c, and LDL-c are measured on an automatic biochemistry analyzer (HITACHI, Inc.; LAbOSPECT, 008AS) using standard reagents to the nearest 0.01 mmol/L.
Time frame: 0-week; 6-week and 12-week
Changes in uric acid (UA)
UA is measured on an automatic biochemistry analyzer (HITACHI, Inc.; LAbOSPECT, 008AS) using standard reagents to the nearest 1 µmol/L.
Time frame: 0-week; 6-week and 12-week
Changes in blood pressure.
Blood pressure is measured in triplicate using a digital automatic blood pressure (Omron HBP-9020, Kyoto, Japan) to the nearest 1 mmHg.
Time frame: 0-week; 6-week and 12-week
Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University